Abstract

Bress et al1 estimated the deaths prevented and excess serious adverse events incurred if the SPRINT (Systolic Blood Pressure Intervention Trial) intensive systolic blood pressure (SBP) treatment goal were implemented in all eligible US adults and observed that, if fully implemented in eligible US adults, intensive SBP treatment could prevent ≈107 500 deaths per year; however, a consequence of this treatment strategy could be an increase in serious adverse events. The best therapeutic target of SBP has been …

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call